<?xml version='1.0' encoding='utf-8'?>
<document id="11499333"><sentence text="Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients." /><sentence text="Superficial fungal infections or tinea infections (also known as the dermatophytoses) are commonly encountered conditions in clinical practice, affecting the skin, hair, and nails" /><sentence text=" The most commonly prescribed modality to treat these infections is topical antifungal therapy" /><sentence text=" However, this method of treating tinea infections may be less convenient and efficacious in the immunocompromised patient" /><sentence text=" In such patients, skin infections are more difficult to treat because the disease is often more extensive and severe" /><sentence text=" Tinea infections of the hair and nails usually require oral therapy" /><sentence text=" Further, topical treatment is not as efficacious as oral antifungal therapy and, with the exception of the topical antifungal agent ciclopirox, is not indicated for the treatment of tinea unguium (onychomycosis)"><entity charOffset="133-143" id="DDI-PubMed.11499333.s7.e0" text="ciclopirox" /></sentence><sentence text=" The 2 most frequently prescribed oral antifungal agents to treat onychomycosis are itraconazole and terbinafine"><entity charOffset="84-96" id="DDI-PubMed.11499333.s8.e0" text="itraconazole" /><entity charOffset="101-112" id="DDI-PubMed.11499333.s8.e1" text="terbinafine" /><pair ddi="false" e1="DDI-PubMed.11499333.s8.e0" e2="DDI-PubMed.11499333.s8.e0" /><pair ddi="false" e1="DDI-PubMed.11499333.s8.e0" e2="DDI-PubMed.11499333.s8.e1" /></sentence><sentence text=" In the general population, both agents are effective in treating fungal nail infections; however, differences in the agents' mechanism of action and metabolic pathways result in differences in efficacy and drug-drug interaction potential" /><sentence text=" However, limited data exist on the use of these agents in immunocompromised patients for the treatment of onychomycosis and superficial tinea infections" /><sentence text=" The available efficacy data we have are limited to case reports or small pilot studies; thus, data supporting the efficacy of these agents for the treatment of tinea infections in the immunocompromised patient must be extrapolated from the general population" /><sentence text=" For safety issues, however, some postmarketing data exist supporting the safety of these agents in the diabetic and human immunodeficiency virus (HIV) patients populations; indeed, both agents appear to be safe" /><sentence text=" However, one contrasting point between these 2 agents is drug interactions" /><sentence text=" Oral terbinafine, unlike itraconazole (a potent cytochrome P-450 [CYP] 3A4 inhibitor), has a relatively low potential for drug-drug interactions, making terbinafine a useful agent for the treatment of tinea infections in immunocompromised patients (e"><entity charOffset="6-17" id="DDI-PubMed.11499333.s14.e0" text="terbinafine" /><entity charOffset="26-38" id="DDI-PubMed.11499333.s14.e1" text="itraconazole" /><entity charOffset="154-165" id="DDI-PubMed.11499333.s14.e2" text="terbinafine" /><pair ddi="false" e1="DDI-PubMed.11499333.s14.e0" e2="DDI-PubMed.11499333.s14.e0" /><pair ddi="false" e1="DDI-PubMed.11499333.s14.e0" e2="DDI-PubMed.11499333.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11499333.s14.e0" e2="DDI-PubMed.11499333.s14.e2" /><pair ddi="false" e1="DDI-PubMed.11499333.s14.e1" e2="DDI-PubMed.11499333.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11499333.s14.e1" e2="DDI-PubMed.11499333.s14.e2" /></sentence><sentence text="g" /><sentence text=", those who are HIV positive and those with diabetes), who are likely to be receiving concomitant medications" /><sentence text=" Further, recently conducted studies of terbinafine for the treatment of tinea pedis, tinea cruris, and tinea corporis infections in these high-risk patient groups also support efficacy claims and reemphasize its relatively safe profile and low potential for drug interactions"><entity charOffset="40-51" id="DDI-PubMed.11499333.s17.e0" text="terbinafine" /></sentence><sentence text=" Additional studies in other immunocompromised patient populations may be useful to confirm recent studies and expand the potential use for this agent" /><sentence text="" /></document>